Clinical trials
Completed Phase 1 Cardiovascular Diseases trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
138 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 2 |
| 2004 | 6 |
| 2005 | 2 |
| 2006 | 3 |
| 2007 | 9 |
| 2008 | 5 |
| 2009 | 11 |
| 2010 | 10 |
| 2011 | 7 |
| 2012 | 2 |
| 2013 | 6 |
| 2014 | 6 |
| 2015 | 4 |
| 2016 | 6 |
| 2017 | 7 |
| 2018 | 11 |
| 2019 | 7 |
| 2020 | 8 |
| 2021 | 4 |
| 2022 | 7 |
| 2023 | 6 |
| 2024 | 4 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 138 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AstraZeneca | 13 |
| Amgen | 5 |
| GlaxoSmithKline | 5 |
| The University of Texas at Arlington | 5 |
| National Heart, Lung, and Blood Institute (NHLBI) | 4 |
| Bial - Portela C S.A. | 3 |
| Chong Kun Dang Pharmaceutical | 3 |
| Humanis Saglık Anonim Sirketi | 3 |
| Northwestern University | 3 |
| Penn State University | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Cardiovascular Diseases | 138 |
| Obesity | 11 |
| Vascular Diseases | 11 |
| Diabetes Mellitus, Type 2 | 9 |
| Hypertension | 9 |
| Atherosclerosis | 7 |
| Coronary Artery Disease | 7 |
| Diabetes Mellitus | 7 |
| Heart Diseases | 6 |
| Heart Failure | 6 |
Trials
Showing 1 to 25 of 138. Each trial links to its page on Pharma Observatory.
38 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.